The global newborn screening market is projected to reach a valuation of US$3.3 Bn by 2031, expanding at a robust compound annual growth rate (CAGR) of approximately 11% during the forecast period. Rising awareness regarding early detection of congenital and inherited disorders, increasing prevalence of critical congenital heart defects, and advancements in diagnostic technologies are contributing to the expansion of the market.
Newborn screening plays an important role in identifying inborn errors of metabolism and other disorders during the first days of a baby's life. Many of these conditions are not immediately apparent at birth but can result in neurological, cognitive, tactile, or physical complications if left undetected. Early diagnosis enables healthcare providers to initiate appropriate interventions and improve the prospects for preventing permanent health problems.
Rising Focus on Early Detection Supports Market Expansion
The increasing prevalence of critical congenital heart defects is a key factor driving demand for newborn screening solutions. Conditions such as pulmonary atresia and tricuspid atresia can require timely intervention, with infants affected by critical congenital heart disease often requiring surgery or other procedures during their first year of life.
In the U.S., congenital heart defects affect an estimated 1% of births, or approximately 40,000 births each year, according to the information cited in the market analysis. About one in four babies with congenital heart defects is affected by critical CHD. These figures highlight the importance of screening programs capable of identifying potentially serious conditions at an early stage.
Healthcare providers and diagnostic technology companies are therefore placing greater emphasis on improving the accuracy and accessibility of newborn screening. The introduction of advanced products based on upgraded techniques is supporting more precise diagnosis of infants, while developments in point-of-care diagnostic devices are creating additional opportunities for market participants.
Connectivity Between Screening Programs and Healthcare Providers
Improved connectivity between public health newborn screening programs and healthcare providers is emerging as another important factor shaping the market. Information management systems and technical assistance can help healthcare organizations coordinate screening activities, communicate results, and support follow-up care.
Initiatives focused on newborn screening interoperability demonstrate the growing importance of connected healthcare infrastructure. Altarum, a nonprofit research and consulting organization, has been selected by the Health Resources and Services Administration (HRSA) to lead the Innovations in Newborn Screening Interoperability Resource Center.
Such initiatives are aimed at strengthening information exchange between screening programs and healthcare providers. Better connectivity can support timely follow-up and contribute to improved medical outcomes for newborns and children.
COVID-19 Highlights Importance of Screening and Follow-up
Newborn health screenings and check-ups have remained important during the coronavirus outbreak, as families and healthcare providers continue to address the health needs of infants. During this period, stakeholders in the newborn screening market have emphasized precautions associated with follow-up testing after screening results are received.
State and territorial newborn screening programs have continued operating as part of essential healthcare services. Providers have also worked to increase access to information concerning screening programs, testing procedures, and follow-up requirements.
Blood spot screening, hearing screening, and critical congenital heart disease testing remain important components of newborn health assessment. Increased availability of contact information and program updates can help families stay informed about screening procedures and subsequent healthcare requirements.
Instruments Segment Expected to Maintain Dominance
Based on product, the global newborn screening market has been segmented into instruments and assay kits. The instruments segment is anticipated to dominate the market during the forecast period. Within instruments, the segment includes tabletop and point-of-care testing technologies.
Growing adoption of technologically advanced screening equipment is supporting demand for instruments capable of delivering accurate and timely diagnostic information. The increasing emphasis on point-of-care testing is also creating opportunities to expand screening access, particularly in settings where conventional laboratory infrastructure may be limited.
Based on test type, the market includes dry blood spot tests, hearing screen tests, critical congenital heart disease (CCHD) tests, X-ray or CT scans, electrocardiogram (ECG) tests, and other testing methods.
Hospitals Represent a Key End-user Segment
By end user, the newborn screening market has been divided into hospitals, diagnostic centers, maternity and specialty clinics, and others. Hospitals dominated the market in terms of revenue in 2019.
The prominent role of hospitals is associated with their ability to provide comprehensive newborn care, screening, diagnosis, and follow-up services. The availability of specialized medical professionals and diagnostic infrastructure also supports the use of multiple screening technologies within hospital settings.
Diagnostic centers and maternity and specialty clinics are expected to remain important participants as healthcare systems seek to broaden access to screening services and improve early detection.
Evaluation of Screening Methods Creates Opportunities
Healthcare organizations and rare disease-focused groups are increasingly evaluating the capacity of existing newborn screening programs to identify infants who could benefit from emerging treatments. Organizations including the EveryLife Foundation for Rare Diseases, Retrophin, Inc., BioMarin Pharmaceutical Inc., Orchard Therapeutics Inc., and Sarepta Therapeutics have collaborated to evaluate newborn screening capabilities in the U.S.
These efforts are focused on supporting timely diagnosis and informing policy recommendations related to equitable access to newborn screening. As the number of conditions potentially assessable through newborn screening increases, healthcare systems also face challenges associated with costs, long-term outcomes, and follow-up data.
The lack of sufficient data regarding the long-term consequences of newly screened pediatric conditions can complicate healthcare decision-making. Standardized approaches to evaluating pediatric health states, including cost-effectiveness and cost-utility analyses, could help address these challenges.
Point-of-Care Innovations Open Opportunities in Emerging Markets
Technological innovation is also creating opportunities beyond established markets. In Africa, rapid point-of-care tools for sickle cell screening are gaining attention. Nigeria, for instance, has introduced a low-cost, 10-minute rapid point-of-care tool that has the potential to expand access to newborn sickle cell screening.
The integration of newborn screening with existing primary healthcare and immunization programs represents another potential avenue for expanding screening coverage in resource-constrained settings. Meanwhile, increased funding and tender opportunities for newborn screening and digital technologies in Europe are supporting efforts to shorten the path to diagnosis for rare diseases.
Competitive Landscape
The global newborn screening market features several established healthcare and diagnostic technology companies. Major players analyzed in the market include PerkinElmer, Inc., Trivitron Healthcare, Natus Medical Incorporated, Medtronic Plc, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, ZenTech S.A., MP BIOMEDICALS, Baebies, Inc., and Masimo.
These companies are focusing on product development, diagnostic accuracy, technological advancement, and expansion of screening capabilities. Their strategies are expected to play a role in shaping the competitive landscape as healthcare providers increasingly seek integrated and efficient newborn screening solutions.
Outlook
The newborn screening market is expected to maintain strong growth through 2031 as healthcare systems place greater emphasis on early diagnosis, prevention of long-term complications, and improved access to screening. Advances in point-of-care technologies, digital connectivity, and diagnostic instruments are likely to remain important market development factors.
At the same time, challenges related to healthcare costs, follow-up data, treatment delays, and the evaluation of newly screenable conditions underscore the need for continued collaboration among healthcare providers, technology companies, researchers, and public health organizations. As screening programs become increasingly connected and technologically advanced, the global newborn screening market is positioned for continued expansion toward its projected US$3.3 Bn valuation by 2031.
